BPC 157 Peptide Research, Benefits & US Sourcing Peptide Intel The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA may be about to change everything for peptide research. Secretary RFK Jr. announced plans to move 14 peptides from Category 2 to Category 1. That means FDA recognized. Potentially prescribable through FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies HHS Secretary RFK Jr. just dropped major news: the FDA is removing 12 peptides from its restrictive Category 2 list reversing the 2023 crackdown that shut down compounding pharmacies and fueled